NCT00090285View on ClinicalTrials.gov

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

PHASE3CompletedINTERVENTIONAL

Enrollment

4,065

Participants

Timeline

Start Date

September 3, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

April 3, 2017

Conditions

Condylomata Acuminata

Interventions

BIOLOGICAL

(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study

BIOLOGICAL

Comparator: placebo (unspecified)

0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00090285 - An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) | Biotech Hunter | Biotech Hunter